Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.
Original title: “FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues”
successful perioperative management of the bentall procedure in a patient with severe hemophilia a infective endocarditis and advanced valve disease
Original title: “Successful Perioperative Management of the Bentall Procedure in a Patient With Severe Hemophilia A, Infective Endocarditis, and Advanced Valve Disease.”
hematoma hemarthrosis and hemotympanum a case report of acquired hemophilia a
Original title: “Hematoma, Hemarthrosis, and Hemotympanum: A Case Report of Acquired Hemophilia A.”
discovery and optimization of marstacimab a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia a and b
Original title: “Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B.”
The estimated mean annualized rate of treated bleeding events decreased by 96.4% in patients treated with denecimig once a week and by 98.7% in those treated once a month, compared with those who continued on-demand treatment. These results support the potential of denecimig as a preventive treatment option for patients with hemophilia A with or without inhibitors, according to Anna Windle, PhD, the head of clinical development, medical, & regulatory affairs at Novo Nordisk US Operations. This article originally appeared on Rare Disease Advisor During the trial, 17 patients continued on-demand treatment, 21 received denecimig once a week, and 20 received denecimig once a month. The estimated mean annualized rate of treated bleeding events was 15.76 in patients continuing on-demand therapy, while it was 0.57 in patients given denecimig once a week and 0.20 in patients given the treatment once a month, corresponding to a relative decrease of 96.4% and 98.7%, respectively. Prophylactic treatment with denecimig is better than on-demand treatment and prophylaxis with clotting factor concentrate in terms of annualized rate of treated bleeding events in patients with hemophilia A. This finding stems from the results of an open-label, randomized, phase 3 clinical trial called FRONTIER2 (NCT05053139), which were published in the New England Journal of Medicine (NEJM). FDA Moves to Real-Time Clinical Trial Patient Monitoring, Faster Drug Review
Original title: “Clinical Trial Results Support the Potential of Denecimig in Hemophilia A - Hematology Advisor”
acquired hemophilia a following influenza vaccination a case report and literature review
Original title: “Acquired hemophilia A following influenza vaccination: a case report and literature review.”
role of dermatologist in diagnosis of acquired a hemophilia
Original title: “The role of dermatologist in diagnosis of acquired A hemophilia.”
crohn s disease complicated by undiagnosed hemophilia a a case of recurrent massive lower gastrointestinal bleeding
Original title: “Crohn's Disease Complicated by Undiagnosed Hemophilia A: A Case of Recurrent Massive Lower Gastrointestinal Bleeding.”
treatment with valoctocogene roxaparvovec in a patient with severe hemophilia a led to sustained normal fviii levels
Original title: “Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.”
understanding treatment care and delays in acquired hemophilia a a population based study from nova scotia canada
Original title: “Understanding Treatment Care and Delays in Acquired Hemophilia A: A Population-Based Study From Nova Scotia, Canada.”
Following the transfer of the IND for giroctocogene fitelparvovec (formerly SB-525, now PF-07055480), we initiated our Phase 3 trial evaluating giroctocogene fitelparvovec gene therapy for the treatment of severe hemophilia A. The future is here. By digging deeper, asking bold questions, and leading scientific innovation, Pfizer Rare Disease is striving to go beyond disease control toward developing potentially transformative medicines and supporting healthy living at all stages of life.
Original title: “Rare Disease Drug Pipeline and Clinical Trials | Pfizer”